Insider · CIK 0001643653

BENEVICH ERIC

Reports to the SEC for 2 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001643653

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-11	NBIXNEUROCRINE BIOSCIENCES INCA Award	Chief Commercial Officer	AAward	+6,275 sh	—	—	70,683
2026-09-11	NBIXNEUROCRINE BIOSCIENCES INCF Tax Payment	Chief Commercial Officer	FTax Payment	−3,386 sh	$156.22	−$529K	67,297
2026-09-09	NBIXNEUROCRINE BIOSCIENCES INCS Sale	Chief Commercial Officer	SSale	−2,154 sh	$154.61	−$333K	64,408
2026-09-09	NBIXNEUROCRINE BIOSCIENCES INC · Incentive Stock OptionM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−3,194 sh	—	—	0
2026-09-09	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+3,194 sh	$43.24	+$138K	66,562
2026-05-11	ATYRaTYR PHARMA INC · Stock Option (right to buy)A Award	Director	AAward	+50K sh	—	—	50,000
2026-02-13	NBIXNEUROCRINE BIOSCIENCES INCF Tax Payment	Chief Commercial Officer	FTax Payment	−1,058 sh	$124.12	−$131K	54,581
2026-02-13	NBIXNEUROCRINE BIOSCIENCES INCA Award	Chief Commercial Officer	AAward	+16.6K sh	—	—	72,153
2026-02-13	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+1,961 sh	—	—	55,639
2026-02-13	NBIXNEUROCRINE BIOSCIENCES INC · Restricted Stock UnitA Award	Chief Commercial Officer	AAward	+6,365 sh	—	—	6,365
2026-02-13	NBIXNEUROCRINE BIOSCIENCES INC · Restricted Stock UnitM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−1,961 sh	—	—	3,924
2026-02-13	NBIXNEUROCRINE BIOSCIENCES INCF Tax Payment	Chief Commercial Officer	FTax Payment	−8,963 sh	$124.12	−$1.11M	63,190
2026-02-13	NBIXNEUROCRINE BIOSCIENCES INC · Stock OptionA Award	Chief Commercial Officer	AAward	+36.3K sh	—	—	36,287
2026-02-13	NBIXNEUROCRINE BIOSCIENCES INC · Restricted Stock UnitM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−2,083 sh	—	—	2,083
2026-02-13	NBIXNEUROCRINE BIOSCIENCES INCF Tax Payment	Chief Commercial Officer	FTax Payment	−1,124 sh	$124.12	−$140K	55,540
2026-02-13	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+2,083 sh	—	—	56,664
2026-02-12	NBIXNEUROCRINE BIOSCIENCES INC · Restricted Stock UnitM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−2,005 sh	—	—	6,017
2026-02-12	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+2,005 sh	—	—	54,760
2026-02-12	NBIXNEUROCRINE BIOSCIENCES INCF Tax Payment	Chief Commercial Officer	FTax Payment	−1,082 sh	$123.10	−$133K	53,678
2026-01-31	NBIXNEUROCRINE BIOSCIENCES INC · Restricted Stock UnitM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−2,294 sh	—	—	0
2026-01-31	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+2,294 sh	—	—	54,047
2026-01-31	NBIXNEUROCRINE BIOSCIENCES INCF Tax Payment	Chief Commercial Officer	FTax Payment	−1,292 sh	$136.06	−$176K	52,755
2025-11-28	NBIXNEUROCRINE BIOSCIENCES INC · Incentive Stock OptionM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−5,970 sh	—	—	6,860
2025-11-28	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+5,970 sh	$35.99	+$215K	50,863
2025-11-28	NBIXNEUROCRINE BIOSCIENCES INC · Incentive Stock OptionM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−12.8K sh	—	—	0
2025-11-28	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+12.8K sh	$35.99	+$462K	57,723
2025-11-28	NBIXNEUROCRINE BIOSCIENCES INCS Sale	Chief Commercial Officer	SSale	−5,970 sh	$151.74	−$906K	44,893
2025-05-01	ATYRaTYR PHARMA INC · Stock Option (right to buy)A Award	Director	AAward	+50K sh	—	—	50,000
2025-02-13	NBIXNEUROCRINE BIOSCIENCES INC · Restricted Stock UnitM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−1,961 sh	—	—	5,885
2025-02-13	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+1,961 sh	—	—	45,745
2025-02-13	NBIXNEUROCRINE BIOSCIENCES INCS Sale	Chief Commercial Officer	SSale	−1,056 sh	$116.71	−$123K	44,689
2025-02-13	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+2,083 sh	—	—	44,882
2025-02-13	NBIXNEUROCRINE BIOSCIENCES INC · Restricted Stock UnitM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−2,083 sh	—	—	4,166
2025-02-13	NBIXNEUROCRINE BIOSCIENCES INCS Sale	Chief Commercial Officer	SSale	−1,098 sh	$116.74	−$128K	43,784
2025-02-12	NBIXNEUROCRINE BIOSCIENCES INC · Restricted Stock UnitA Award	Chief Commercial Officer	AAward	+8,022 sh	—	—	8,022
2025-02-12	NBIXNEUROCRINE BIOSCIENCES INC · Stock OptionA Award	Chief Commercial Officer	AAward	+42.8K sh	—	—	42,805
2025-02-10	NBIXNEUROCRINE BIOSCIENCES INCS Sale	Chief Commercial Officer	SSale	−980 sh	$118.31	−$116K	42,799
2025-02-08	NBIXNEUROCRINE BIOSCIENCES INC · Restricted Stock UnitM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−1,860 sh	—	—	0
2025-02-08	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+1,860 sh	—	—	43,779
2025-01-31	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+2,294 sh	—	—	43,126
2025-01-31	NBIXNEUROCRINE BIOSCIENCES INCS Sale	Chief Commercial Officer	SSale	−1,207 sh	$152.94	−$185K	41,919
2025-01-31	NBIXNEUROCRINE BIOSCIENCES INC · Restricted Stock UnitM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−2,294 sh	—	—	2,294
2024-12-10	ATYRaTYR PHARMA INC · Stock Option (right to buy)A Award	Director	AAward	+100K sh	—	—	100,000
2024-04-15	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+7,231 sh	$81.49	+$589K	48,009
2024-04-15	NBIXNEUROCRINE BIOSCIENCES INCS Sale	Chief Commercial Officer	SSale	−7,231 sh	$133.36	−$964K	40,778
2024-04-15	NBIXNEUROCRINE BIOSCIENCES INC · Non-Qualified Stock OptionM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−7,231 sh	$81.49	−$589K	26,292
2024-04-15	NBIXNEUROCRINE BIOSCIENCES INCS Sale	Chief Commercial Officer	SSale	−12.6K sh	$133.36	−$1.68M	40,778
2024-04-15	NBIXNEUROCRINE BIOSCIENCES INC · Non-Qualified Stock OptionM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−12.6K sh	$81.05	−$1.02M	0
2024-04-15	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+12.6K sh	$81.05	+$1.02M	53,365
2024-03-14	NBIXNEUROCRINE BIOSCIENCES INC · Non-Qualified Stock OptionM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−69.5K sh	$81.05	−$5.63M	12,587

Recent filings

Accepted (ET)
Sep 154
BENEVICH ERIC0001643653-26-000018
SEC(opens sec.gov)
Sep 104
BENEVICH ERIC0001643653-26-000016
SEC(opens sec.gov)
May 134
BENEVICH ERIC0001643653-26-000014
SEC(opens sec.gov)
Feb 174
BENEVICH ERIC0001643653-26-000011
SEC(opens sec.gov)
Feb 34
BENEVICH ERIC0001643653-26-000008
SEC(opens sec.gov)

Companies

Address

6027 EDGEWOOD BEND CT.

SAN DIEGO, CA, 92130